vimarsana.com

Page 2 - எங்களுக்கு தேசிய கண் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global $93 8 Billion Vision Care Market to 2027: Increasing Awareness About Vision Care & Development of Innovative Products

Lacson: Born nearsighted

SunStar May 10, 2021 WHEN I was about 10 years old, I had difficulties reading what was being written in the black board. Often times, I had to squirm my face and struggle just to be able to see what’s in front of me. I did not really understand what was going on, and I can remember quite a few times when I would stare at the façade of our house and see a blurred and distorted version of it. Then, at a later time of those mornings, I would experience terrible headaches that would turn into nausea and vomiting. After suffering from all these, I finally learned that I had myopia.

K-pop group Monsta X s Shownu suffers complications from eye surgery – Manila Bulletin

Published May 3, 2021, 8:06 PM Monsta X’s Shownu (Starship)  K-pop boy band Monsta X’s leader Shownu will take a break after he suffered complications from his eye surgery last year. In a statement, Starship Entertainment, Monsta X’s agency, said, “In July 2020, Shownu was diagnosed with ‘Left Retinal Detachment (Amotio Retinae)’ and had to undergo emergency surgery following the official diagnosis from the specialist.” According to the US National Eye Institute, “Retinal detachment is an eye problem that happens when your retina (a light-sensitive layer of tissue in the back of your eye) is pulled away from its normal position at the back of your eye.”

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device News provided by Share this article New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery LAVAL, QC, April 7, 2021 /PRNewswire/  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. The ClearVisc™ dispersive OVD is the latest advancement in Bausch + Lomb s rich pipeline of ophthalmic surgical devices and is representative of our company s ongoing commitment to delivering innovations that fulfill the unmet needs of our customers, said Joe Gordon, U.S. president, Bausch + Lomb. OVDs play a critical role in cataract surgery as well as many other ophthalmic surgeries. ClearVisc™ offers significant advantages that can help surge

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.